Abstract:In this study, we described a series of 2,8-diazaspiro[4.5]decan-1-one derivatives as selective TYK2/JAK1 inhibitors. Systematic exploration of the structure–activity relationship through the introduction of spirocyclic scaffolds based on the reported selective TYK2 inhibitor 14l led to the discovery of the superior derivative compound 48. Compound 48 showed excellent potency on TYK2/JAK1 kinases with IC50 values of 6 and 37 nM, respectively, and exhibited more than 23-fold selectivity for JAK2. Compound 48 also demonstrated excellent metabolic stability and more potent anti-inflammatory efficacy than tofacitinib in acute ulcerative colitis models. Moreover, the excellent anti-inflammatory effect of compound 48 was mediated by regulating the expression of related TYK2/JAK1-regulated genes, as well as the formation of Th1, Th2, and Th17 cells. Taken together, these findings suggest that compound 48 is a selective dual TYK2/JAK inhibitor, deserving to be developed as a clinical candidate.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c01137.Listing the metabolic stability of the preferred compounds (Table S1); listing binding affinities of 48 with 110 protein kinases (Table S2); listing the disease activity index (DAI) scoring system (Table S3); listing the IL-6, TNF-α, and IL-10 concentrations in Serum of UC Mice (Table S4); listing the primer sequence (Table S5); listing the docking results of compounds 48, 8, and 11 (Figure S1); listing the inhibition patterns of compound 48 and different drugs on different phosphorylated STATs (Figure S2); listing the relative gray quantitative analysis of p-STATs after treatment of 48 (Figure S3); listing the inhibitory effect of compound 48 on the p-STAT3 after cytokine stimulation (Figure S4); listing the in vivo assays of tissue distribution mice (Figure S5); listing the HE staining of heart, liver, spleen, lungs, and kidneys (Figure S6); listing the detection of levels of proteins in the colon tissue of UC mice by western blot (Figure S7); listing the effect of 48 on the expression of Th1, Th2, and Th17 cells (Figure S8); listing the HPLC of compounds 8, 33, 41, 48, and 49, respectively (Figures S9–S13); listing F-NMR spectra of compound 48 (Figure S14) (PDF)jmcmar_mfs (CSV)Compound 48-JAK1-6DBN (PDB)Compound 48-TYK2-6DBK (PDB)Compound 8-JAK1-6DBN (PDB)Compound 8-TYK2-6DBK (PDB)Compound 11-JAK1-6DBN (PDB)Compound 11-TYK2-6DBK (PDB)This article has not yet been cited by other publications.

Discovery of Selective P2Y6R Antagonists with High Affinity and in Vivo Efficacy for Inflammatory Disease Therapy

Discovery of a potent, Highly selective, and In vivo anti-inflammatory Efficacious, P2Y 6 R antagonist with a novel quinoline-pyrazole scaffold

Design,Synthesis and Biological Evaluation of Potent and Selective S1PR1 Agonists for the Treatment of Ulcerative Colitis

Functionalized Congeners of 2H-Chromene P2Y6 Receptor Antagonists

Synthesis and Anti-Inflammatory Bowel Disease Activity of Pterostilbene Derivatives

Discovery of novel aporphine alkaloid derivative as potent TLR2 antagonist reversing macrophage polarization and neutrophil infiltration against acute inflammation

Discovery of 4-((E)-3,5-dimethoxy-2-((E)-2-nitrovinyl)styryl)aniline derivatives as potent and orally active NLRP3 inflammasome inhibitors for colitis

Discovery of Novel Pterostilbene-Based Derivatives as Potent and Orally Active NLRP3 Inflammasome Inhibitors with Inflammatory Activity for Colitis

From lead to clinic: A review of the structural design of P2X7R antagonists

Discovery and Optimization of 4-Oxo-2-thioxo-thiazolidinones As NOD-like Receptor (NLR) Family, Pyrin Domain-Containing Protein 3 (NLRP3) Inhibitors.

Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders

Discovery of Triazinone Derivatives as Novel, Specific, and Direct NLRP3 Inflammasome Inhibitors for the Treatment of DSS-Induced Ulcerative Colitis

Design, synthesis and biological evaluation of novel diphenylamine analogues as NLRP3 inflammasome inhibitors

Discovery of a Highly Potent Oxysterol Receptor GPR183 Antagonist Bearing the Benzo[ d ]thiazole Structural Motif for the Treatment of Inflammatory Bowel Disease (IBD)

Discovery of 4-Benzyloxybenzo[d]isoxazole-3-amine Derivatives As Highly Selective and Orally Efficacious Human Sphingomyelin Synthase 2 Inhibitors That Reduce Chronic Inflammation in Db/db Mice

Discovery of Triazolopyrimidine Derivatives as Selective P2X3 Receptor Antagonists Binding to an Unprecedented Allosteric Site as Evidenced by Cryo-Electron Microscopy

Identification of a Novel 2,8-Diazaspiro[4.5]decan-1-one Derivative as a Potent and Selective Dual TYK2/JAK1 Inhibitor for the Treatment of Inflammatory Bowel Disease

Discovery of N-Substituted Acetamide Derivatives as Promising P2Y 14 R Antagonists Using Molecular Hybridization Based on Crystallographic Overlay

Discovery of 6‐Acylamino/Sulfonamido Benzoxazolone with IL‐6 Inhibitory Activity as Promising Therapeutic Agents for Ulcerative Colitis

Structural Insights into Selective and Dual Antagonism of EP2 and EP4 Prostaglandin Receptors

Discovery of 2 H -Indazole-3-carboxamide Derivatives as Novel Potent Prostanoid EP4 Receptor Antagonists for Colorectal Cancer Immunotherapy.